The Schizophrenia–Rheumatoid Arthritis Connection: Infectious, Immune, or Both?

doi:10.1006/brbi.2001.0649

Brain, Behavior, and Immunity

Volume 15, Issue 4, December 2001, Pages 401-410

https://doi.org/10.1006/brbi.2001.0649 Get rights and content

Abstract

Schizophrenia and rheumatoid arthritis share an impressive number of similarities. Both are chronic, relapsing diseases of unknown etiology. Both became prominent in the early 19th century and have prevalences of approximately 1% in North America and Europe. Both run in families, have pairwise concordance rates of approximately 30% among monozygotic twins, and are more common among individuals born in urban areas. For both diseases, studies have reported greater exposure to cats in childhood than in controls. Both diseases have been associated with similar class II HLA antigens. Both have also been suspected of having infectious etiology, with similar agents—retroviruses, herpesviruses including EBV, and Toxoplasma gondii—having been associated in some cases. Since there is also a well-documented inverse correlation between these two diseases, it is possible that they share a common infectious and/or immune etiology and that once a person gets one of the diseases then they are relatively immune to the other.

References (69)

C. Bond et al.
Rheumatoid arthritis: Are pets implicated in its etiology?
Semin. Arthritis Rheum.
(1996)
A. Brand et al.
Human retrovirus-5 in rheumatic disease
Autoimmunity
(1999)
W.W. Buchanan et al.
Month of birth and rheumatoid arthritis
Lancet
(1987)
P. Deb-Rinker et al.
Molecular characterization of a MSRV-like sequence identified by RDA from monozygotic twin pairs discordant for schizophrenia
Genomics
(1999)
W.W. Eaton et al.
Schizophrenia and rheumatoid arthritis: A review
Schizophr. Res.
(1992)
W.F. Gattaz et al.
Arthropathies and schizophrenia
Lancet
(1980)
C.M. Gilvarry et al.
Family history of autoimmune diseases in psychosis
Schizophr. Res.
(1996)
D.J. Hart et al.
Antiretroviral antibodies: Implications for schizophrenia, schizophrenia spectrum disorders, and bipolar disorder
Biol. Psychiatry
(1999)
R.E. Holliman
RE Toxoplasmosis, behaviour and personality
J. Infect.
(1997)
E.G. Jönsson et al.
Lack of association between schizophrenia and HLA DQBI alleles in a Swedish sample
Schiz. Res.
(1998)

Y.K. Kim et al.

Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics

Schizophr. Res.

(2000)

G.E. Loxton et al.

The aetiology of rheumatoid arthritis

Lancet

(1961)

O. Mors et al.

A population-based register study of the association between schizophrenia and rheumatoid arthritis

Schizophr. Res.

(1999)

P.S. Penglis et al.

Genetic susceptibility and the link between cat exposure and rheumatoid arthritis

Semin. Arthritis Rheum.

(2000)

T. Sasaki et al.

HLA-DR types in Japanese schizophrenics: Analysis by group-specific PCR amplification

Schizophr. Res.

(1994)

C. Sellar et al.

Season of birth, year of birth, and arthritic disease in later life

Lancet

(1988)

T.D. Spector

Rheumatoid arthritis

Rheum. Dis. Clin. North Am.

(1990)

E.F. Torrey et al.

Seasonality of births in schizophrenia and bipolar disorder: A review of the literature

Schizophr. Res.

(1997)

R. Winchester

The molecular basis of susceptibility to rheumatoid arthritis

Adv. Immunol.

(1994)

P. Wright et al.

Schizophrenia and HLA: A review

Schizophr. Res.

(2001)

R.H. Yolken et al.

Endogenous retroviruses and schizophrenia

Brain Res. Brain Res. Rev.

(2000)

E. Balleari et al.

Adult-onset Still's disease associated to toxoplasma gondii infection

Clin. Rheumatol.

(1991)

Buka, S. L, Tsuang, M. T, Torrey, E. F, Klebanoff, M. A, Bernstein, D, &, Yolken, R. H. Maternal infections and...

L.A. Criswell et al.

Update on genetic risk factors for systemic lupus erythematosus and rheumatoid arthritis

Am. J. Hum. Gene.

(2001)

G. Delgado Garcia et al.

Reactivity of the intradermal test with toxoplasmosis in schizophrenic patients

Rev. Cubana Med. Trop.

(1979)

T. Drecke

On the germ-theory of disease

Am. J. Insanity

(1874)

W.J. Fessel

Disturbed serum proteins in chronic psychosis

Arch. Gen. Psychiatry

(1961)

R. Ganguli et al.

Autoimmunity in schizophrenia: A review of recent findings

Ann. Med.

(1993)

Gilmore, J. H, Gu, H, Yolken, R. H, Phillips, M, Yang, F.-D, Bilder, R. M, &, Lieberman, J. A. 2000, Toxoplasma...

N.L. Gottlieb et al.

Pets and rheumatoid arthritis

Arthritis Rheum.

(1974)

T. Gotlieb-Stematsky et al.

Antibodies to Epstein-Barr virus, herpes simplex type 1, cytomegalovirus and measles virus in psychiatric patients

Arch. Virol.

(1981)

T. Hasunuma et al.

Human T cell leukemia virus type-I and rheumatoid arthritis

Int. Rev. Immunol.

(1998)

R.G. Health et al.

Schizophrenia as an immunologic disorder [3 parts]

Arch. Gen. Psychiatry

(1967)

T. Hishikawa et al.

Detection of antibodies to a recombinant gag protein derived from human endogenous retrovirus clone 4-1 in autoimmune diseases

Viral Immunol.

(1997)

Cited by (111)

The association between Toxoplasma gondii infection and postpartum blues
2019, Journal of Affective Disorders
Citation Excerpt :
However, considering an extended set of disease conditions, evidence is accumulating that strongly suggests that this parasite may be implicated in neurodegenerative diseases and are gradually emerging as a global health threat (Furtado et al., 2011; Torgerson and Mastroiacovo, 2013). For example, chronic infection with T. gondii is more frequent in individuals with schizophrenia than in psychiatrically healthy controls, as indicated in several studies from different countries (Torrey and Yolken, 2001, 2003; Torrey et al., 2007). In addition, a number of studies have also demonstrated that T. gondii seropositivity is related to personality changes and various mental disorders including development of suicidal tendencies, obsessive compulsive disorder, bipolar disorder, and depression (Sutterland et al., 2015; Arling et al., 2009; Hinze-Selch et al., 2010; Ling et al., 2011; Okusaga et al., 2011; Tedla et al., 2011).
Toxoplasma gondii is an intracellular protozoan parasite infecting approximately 30% of the global human population. It has often been suggested that chronic infection with T. gondii is related to personality changes and various mental disorders including depression. It is not known whether this includes post-partum blues or depression. In this study, we test the hypothesis that there is a relationship between T. gondii infection and post-partum blues by measuring the association between infection and postpartum blues.
A total of 475 Chinese women who have just given birth were detected serology for Toxoplasma IgG and IgM antibodies, and evaluated the degree of depression by Hamilton Depression Scale (HAMD) score. Data were analyzed by Chi-square or Fisher's Exact tests using SPSS software.
We found an overall Toxoplasma seroprevalence of 5.68% (27/475; 95% CI: 3.59–7.77) which was broken down into a prevalence of 6.60% (7/106; 95% CI: 1.80–11.41) in mothers with post-partum blues and 5.42% (20/369; 95% CI: 3.10–7.74) in non-affected mothers. There was no significant association between infection and post-partum blues (p = 0.64).
The results suggest that there is no relationship between T. gondii infection and postpartum blues, at least in this sample of patients from China.
Autoimmune phenotypes in schizophrenia reveal novel treatment targets
2018, Pharmacology and Therapeutics
Citation Excerpt :
A similar dysregulation of adaptive and cellular immunity is increasingly demonstrated in schizophrenia, suggesting that this disorder, although not a classic autoimmune disease, may share some common, potentially treatable, physiological features. Early records examining the associations between autoimmune disorders and schizophrenia document the discovery of an inverse correlation in prevalence between rheumatoid arthritis and schizophrenia, and this relationship was also more recently replicated (Chen et al., 2012; Eaton, Hayward, & Ram, 1992; Gorwood et al., 2004; Sellgren, Frisell, Lichtenstein, Landen, & Askling, 2014; Torrey & Yolken, 2001; Trevathan & Tatum, 1953). Other investigations, including some recent large-scale birth registry studies, found a positive association between an array of autoimmune disorders (including multiple sclerosis, systemic lupus erythematosus, autoimmune thyrotoxicosis, autoimmune hepatitis and psoriasis) and a diagnosis of schizophrenia or psychosis (Benros, Eaton, & Mortensen, 2014; Chen et al., 2012; Eaton et al., 2006; Gilvarry et al., 1996; Wright et al., 1996).
Typical and atypical antipsychotics are the first-line treatments for schizophrenia, but these classes of drugs are not universally effective, and they can have serious side effects that impact compliance. Antipsychotic drugs generally target the dopamine pathways with some variation. As research of schizophrenia pathophysiology has shifted away from a strictly dopamine-centric focus, the development of new pharmacotherapies has waned. A field of inquiry with centuries-old roots is gaining traction in psychiatric research circles and may represent a new frontier for drug discovery in schizophrenia. At the forefront of this investigative effort is the immune system and its many components, pathways and phenotypes, which are now known to actively engage the brain. Studies in schizophrenia reveal an intricate association of environmentally-driven immune activation in concert with a disrupted genetic template. A consistent conduit through this gene-environmental milieu is the gut-brain axis, which when dysregulated can generate pathological autoimmunity. In this review, we present epidemiological and biochemical evidence in support of an autoimmune component in schizophrenia and depict gut processes and a dysbiotic microbiome as a source and perpetuator of autoimmune dysfunction in the brain. Within this framework, we review the role of infectious agents, inflammation, gut dysbioses and autoantibody propagation on CNS pathologies such as neurotransmitter receptor hypofunction and complement pathway-mediated synaptic pruning. We then review the new pharmacotherapeutic horizon and novel agents directed to impact these pathological conditions. At the core of this discourse is the understanding that schizophrenia is etiologically and pathophysiologically heterogeneous and thus its treatment requires individualized attention with disease state variants diagnosed with objective biomarkers.
Prevalences of autoimmune diseases in schizophrenia, bipolar I and II disorder, and controls
2017, Psychiatry Research
Citation Excerpt :
This has led to the hypothesis that schizophrenia is a protective factor for RA. The interplay of genetic (Benros et al., 2014a, 2014b; Leucht et al., 2007), environmental, immunological, and pharmacological factors (Torrey and Yolken, 2001) has been suggested as potential mediators. Our finding of a similar RA prevalence among schizophrenic patients and controls thus conflicts with this line of evidence.
Previous studies on the relationship between autoimmune diseases, schizophrenia, and bipolar disorder are mainly based on hospital discharge registers with insufficient coverage of outpatient data. Furthermore, data is scant on the prevalence of autoimmune diseases in bipolar subgroups. Here we estimate the self-reported prevalences of autoimmune diseases in schizophrenia, bipolar disorder type I and II, and controls. Lifetime prevalence of autoimmune diseases was assessed through a structured interview in a sample of 9076 patients (schizophrenia N = 5278, bipolar disorder type I N = 1952, type II N = 1846) and 6485 controls. Comparative analyses were performed using logistic regressions. The prevalence of diabetes type 1 did not differ between groups. Hyperthyroidism, hypothyroidism regardless of lithium effects, rheumatoid arthritis, and polymyalgia rheumatica were most common in bipolar disorder. Systemic lupus erythematosus was less common in bipolar disorder than in the other groups. The rate of autoimmune diseases did not differ significantly between bipolar subgroups. We conclude that prevalences of autoimmune diseases show clear differences between schizophrenia and bipolar disorder, but not between the bipolar subgroups.
Neuroimmune biomarkers in schizophrenia
2016, Schizophrenia Research
Schizophrenia is a heterogeneous psychiatric disorder with a broad spectrum of clinical and biological manifestations. Due to the lack of objective tests, the accurate diagnosis and selection of effective treatments for schizophrenia remains challenging. Numerous technologies have been employed in search of schizophrenia biomarkers. These studies have suggested that neuroinflammatory processes may play a role in schizophrenia pathogenesis, at least in a subgroup of patients. The evidence indicates alterations in both pro- and anti-inflammatory molecules in the central nervous system, which have also been found in peripheral tissues and may correlate with schizophrenia symptoms. In line with these findings, certain immunomodulatory interventions have shown beneficial effects on psychotic symptoms in schizophrenia patients, in particular those with distinct immune signatures. In this review, we evaluate these findings and their potential for more targeted drug interventions and the development of companion diagnostics. Although currently no validated markers exist for schizophrenia patient stratification or the prediction of treatment efficacy, we propose that utilisation of inflammatory markers for diagnostic and theranostic purposes may lead to novel therapeutic approaches and deliver more effective care for schizophrenia patients.
Autoimmune diseases, gastrointestinal disorders and the microbiome in schizophrenia: more than a gut feeling
2016, Schizophrenia Research
Citation Excerpt :
Each of these hypotheses was evaluated in studies with research designs that effectively discounted those explanations (Trevathan and Tatum, 1953; Pilkington, 1955; Mellsop et al., 1974; Mohamed et al., 1982). There have been several studies of genes, immune-related factors, and common infections which might explain the inverse association (Taylor, 1978; Hopkins et al., 1988; Wright et al., 1998; Torrey and Yolken, 2001; Genevay et al., 2002; de la Fontaine et al., 2006), including a compelling meta-analysis showing that the antagonist to the receptor of the inflammatory cytokine IL-1 was more prevalent in individuals with schizophrenia, thus protecting them from rheumatoid arthritis (Potvin et al., 2008). Autoimmune disorders can be triggered by dietary components and antigens derived from the GI tract.
Autoimmunity, gastrointestinal (GI) disorders and schizophrenia have been associated with one another for a long time. This paper reviews these connections and provides a context by which multiple risk factors for schizophrenia may be related. Epidemiological studies strongly link schizophrenia with autoimmune disorders including enteropathic celiac disease. Exposure to wheat gluten and bovine milk casein also contribute to non-celiac food sensitivities in susceptible individuals. Co-morbid GI inflammation accompanies humoral immunity to food antigens, occurs early during the course of schizophrenia and appears to be independent from antipsychotic-generated motility effects. This inflammation impacts endothelial barrier permeability and can precipitate translocation of gut bacteria into systemic circulation. Infection by the neurotropic gut pathogen, Toxoplasma gondii, will elicit an inflammatory GI environment. Such processes trigger innate immunity, including activation of complement C1q, which also functions at synapses in the brain. The emerging field of microbiome research lies at the center of these interactions with evidence that the abundance and diversity of resident gut microbiota contribute to digestion, inflammation, gut permeability and behavior. Dietary modifications of core bacterial compositions may explain inefficient gluten digestion and how immigrant status in certain situations is a risk factor for schizophrenia. Gut microbiome research in schizophrenia is in its infancy, but data in related fields suggest disease-associated altered phylogenetic compositions. In summary, this review surveys associative and experimental data linking autoimmunity, GI activity and schizophrenia, and proposes that understanding of disrupted biological pathways outside of the brain can lend valuable information regarding pathogeneses of complex, polygenic brain disorders.
Role of Immune and Autoimmune Dysfunction in Schizophrenia
2016, Handbook of Behavioral Neuroscience
In this chapter, we review data in support of the concept that immune system dysregulation is the most plausible explanation that reconciles gene by environmental interactions in schizophrenia. Early investigations of this topic demonstrated aspects of aberrant activation of humoral immunity, including autoimmunity, associated with schizophrenia, whereas current research efforts have expanded this theme to include elements of innate immunity. Advances in our understanding of inflammation and molecules of both the adaptive and innate immune system and their functional roles in standard brain physiology provide an important context by which schizophrenia might arise as the result of the coupling of immune and neurodevelopmental dysregulation.

View all citing articles on Scopus

View full text

Regular ArticleThe Schizophrenia–Rheumatoid Arthritis Connection: Infectious, Immune, or Both?

Abstract

Semin. Arthritis Rheum.

Autoimmunity

Lancet

Genomics

Schizophr. Res.

Lancet

Schizophr. Res.

Biol. Psychiatry

J. Infect.

Schiz. Res.

Schizophr. Res.

Lancet

Schizophr. Res.

Semin. Arthritis Rheum.

Schizophr. Res.

Lancet

Rheum. Dis. Clin. North Am.

Schizophr. Res.

Adv. Immunol.

Schizophr. Res.

Brain Res. Brain Res. Rev.

Adult-onset Still's disease associated to toxoplasma gondii infection

Clin. Rheumatol.

Update on genetic risk factors for systemic lupus erythematosus and rheumatoid arthritis

Am. J. Hum. Gene.

Reactivity of the intradermal test with toxoplasmosis in schizophrenic patients

Rev. Cubana Med. Trop.

On the germ-theory of disease

Am. J. Insanity

Disturbed serum proteins in chronic psychosis

Arch. Gen. Psychiatry

Autoimmunity in schizophrenia: A review of recent findings

Ann. Med.

Pets and rheumatoid arthritis

Arthritis Rheum.

Antibodies to Epstein-Barr virus, herpes simplex type 1, cytomegalovirus and measles virus in psychiatric patients

Arch. Virol.

Human T cell leukemia virus type-I and rheumatoid arthritis

Int. Rev. Immunol.

Schizophrenia as an immunologic disorder [3 parts]

Arch. Gen. Psychiatry

Detection of antibodies to a recombinant gag protein derived from human endogenous retrovirus clone 4-1 in autoimmune diseases

Viral Immunol.

Regular Article
The Schizophrenia–Rheumatoid Arthritis Connection: Infectious, Immune, or Both?